Expression vector for anti-SARS-CoV-2 neutralizing antibodies
US11312760B1 · kind B1 · utility
1Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2021 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Aug 2, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides recombinant expression vectors expressing a novel neutralizing antibodies against SARS-COV-2, or the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.